<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03695445</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT2018-002158-59</org_study_id>
    <secondary_id>2018-002158-59</secondary_id>
    <nct_id>NCT03695445</nct_id>
  </id_info>
  <brief_title>Safety of Norepinephrine Administered Through Peripheral Venous Catheter</brief_title>
  <official_title>A Prospective Study of the Safety of Norepinephrine Administered Through Peripheral Venous Catheter During Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christer Svensen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Norepinephrine is a drug that elevates the blood pressure. It is routinely administered
      through peripheral catheters during surgery. There is a risk of tissue damage in case of
      leakage of Norepinephrine from the catheter to the surrounding tissue. Another risk is
      irregular administration of Norepinephrine due to kinking of the peripheral catheter. This
      could lead to fluctuations in blood pressure. The primary aim of the study is to investigate
      complications from Norepinephrine administered in peripheral venous catheters. The secondary
      aim is to investigate if comorbidity, placement of the peripheral catheter or the duration of
      the infusion are associated with a higher rate of complications. 1000 patients will be
      included. Inclusion criteria: Patients who will undergo surgery with need for vasopressor
      support. Exclusion criteria: The patient has a central venous catheter, a peripherally
      inserted central venous catheter or lack of informed consent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In many hospitals in Sweden, Norepinephrine is administered through peripheral venous
      catheters in the operating room. However there are very few studies to support the safety of
      peripherally administered Norepinephrine.

      Norepinephrine of the concentration 8 respectively 40 microg/ml will be investigated. The
      primary aim of the study is to investigate complications from Norepinephrine administered in
      peripheral venous catheters. The secondary aim is to investigate if comorbidity, placement of
      the peripheral catheter or the duration of the infusion are associated with a higher rate of
      complications.

      The localisation and size of the peripheral venous catheter will be registered. The blood
      pressure will me measured every 5 minutes and every minute in case of systolic blood pressure
      over 220 mm Hg.

      The site of administration will regularly be monitored for complications. If subcutaneous
      infusion of Norepinephrine is suspected, the patient will be followed up for up to 48 hours
      or until hospital discharge.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 29, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with treatment-related adverse events</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Proportion of patients with complications (Subcutaneous infusion and/or hypertension&gt;220 mmHg and/or heart rate&lt;40 beats/min)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association between comorbidity, placement of catheter, duration of infusion and increased proportion of complications</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Odds ratio of Treatment-Emergent Adverse Events in risk groups (ASA&gt;2, placement of catheter distal to the antecubital or popliteal fossae, duration of infusion&gt; 4 hours)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Hypotension</condition>
  <arm_group>
    <arm_group_label>Peripheral Norepinephrine</arm_group_label>
    <description>Patients who will undergo surgery with need for vasopressor support.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peripheral administration of Norepinephrine</intervention_name>
    <description>Systematic follow-up of complications from peripheral administration of Norepinephrine</description>
    <arm_group_label>Peripheral Norepinephrine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who require vasopressors to maintain an adequate blood pressure during general
        anesthesia and/or central blocks.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who has general anesthesia or central blocks

          -  Need for vasopressors in the pre, per or postoperative period to maintain adequate
             mean arterial blood pressure

          -  Age ≥18 years

        Exclusion Criteria:

          -  The patient has a central venous line

          -  The patient has a peripherally inserted central line

          -  Lack of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Andersson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stockholm South General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Cronhjort, MD, PhD</last_name>
    <phone>+4686162965</phone>
    <email>maria.cronhjort@sll.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabeth Andersson, MD</last_name>
    <phone>+4686161000</phone>
    <email>elisabeth.ce.andersson@sll.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Danderyds sjukhus</name>
      <address>
        <city>Stockholm</city>
        <state>Danderyd</state>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olof Wall, MD</last_name>
      <phone>+46812358374</phone>
      <email>olof.wall@telia.com</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Törnberg, MD, PhD</last_name>
      <email>daniel.tornberg@sll.se</email>
    </contact_backup>
    <investigator>
      <last_name>Olof Wall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Törnberg, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Cronhjort, MD, PhD</last_name>
      <phone>+466161000</phone>
      <email>maria.cronhjort@sll.se</email>
    </contact>
    <contact_backup>
      <last_name>Elisabeth Andersson, MD</last_name>
      <phone>+4686161000</phone>
      <email>elisabeth.ce.andersson@sll.se</email>
    </contact_backup>
    <investigator>
      <last_name>Maria Cronhjort, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva Joelsson-Alm, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabeth Andersson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johan Mårtensson, Ass Prof</last_name>
      <phone>+46851770000</phone>
      <email>johan.martensson@sll.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 14, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2018</study_first_posted>
  <last_update_submitted>March 5, 2019</last_update_submitted>
  <last_update_submitted_qc>March 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Christer Svensen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

